Equities

Dextech Medical AB

Dextech Medical AB

Actions
  • Price (EUR)0.34
  • Today's Change-0.002 / -0.58%
  • Shares traded-1.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of May 16 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Dextech Medical AB is a Sweden-based research company specialized in urologic oncology. It is focused on prostate cancer, but also other cancers and non-malignant diseases. It develops drug canditates based on modified carbohydrate molecule combined with active substances. The Company has a patented technology platform, GuaDex, and three drug candidates with patents or patent applications. The portfolio includes: OsteoDex, for treatment of bone metastases in castration resistant prostate cancer (CRPC); SomaDex, based on endogenous hormone, somatostatin, and aimed at treatment of acromegaly, neuroendocrine tumors and palliative treatment of CRPC; and CatDex, for instillation treatment of bladder cancer.

  • Revenue in SEK (TTM)0.00
  • Net income in SEK-4.53m
  • Incorporated2004
  • Employees1.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.